Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Lung Yu

Showing results (21-30 of 616) with videos related to

Pageof 62
Sort By:
Journal of the Formosan Medical Association = Taiwan Yi Zhi|January 10, 2021
Reply to "Tacrolimus concentrations were not affected by glecaprevir/pibrentasvir treatment for hepatitis C virus infection in an adult living donor liver transplant recipient with uremia"Ming-Lung Yu, Jia-Horng Kao
Clinical and Molecular Hepatology|March 20, 2020
Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapyChung-Feng Huang, Ming-Lung Yu
The Journal of Infectious Diseases|September 13, 2023
Sharing Lessons Learned to Build Effective Hepatitis Elimination ProgramsMing-Lung Yu, John W Ward
Alimentary Pharmacology & Therapeutics|May 15, 2026
Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline-A Step Toward Functional Cure or a Marginal Margin?Yao-Chun Hsu, Ming-Lung Yu
Clinical and Molecular Hepatology|February 19, 2024
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answerPin-Nan Cheng, Ming-Lung Yu
Clinical and Molecular Hepatology|March 5, 2024
Correspondence on Letter regarding "Toward hepatitis C virus elimination using artificial intelligence"Ming-Ying Lu, Ming-Lung Yu
The Kaohsiung Journal of Medical Sciences|November 27, 2023
Hepatitis C virus micro-elimination in people who inject drugs: Challenges and chance in Taiwan and worldwideChi-Ming Tai, Ming-Lung Yu
Clinical and Molecular Hepatology|February 12, 2019
Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?Chung-Feng Huang, Ming-Lung Yu
Journal of the Formosan Medical Association = Taiwan Yi Zhi|July 26, 2018
Reply to "Rescue for interferon failures in HCV genotype 1/HBV dually infection"Meng-Hsuan Hsieh, Ming-Lung Yu
Hepatitis Research and Treatment|January 22, 2011
Pegylated interferon and ribavirin treatment for hepatitis C virus infectionTatehiro Kagawa, Emmet B Keeffe, Ming-Lung Yu
Pageof 62

Showing results (21-30 of 616) with videos related to

Sort By:
Pageof 62
Journal of the Formosan Medical Association = Taiwan Yi Zhi|January 10, 2021
Reply to "Tacrolimus concentrations were not affected by glecaprevir/pibrentasvir treatment for hepatitis C virus infection in an adult living donor liver transplant recipient with uremia"Ming-Lung Yu, Jia-Horng Kao
Clinical and Molecular Hepatology|March 20, 2020
Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapyChung-Feng Huang, Ming-Lung Yu
The Journal of Infectious Diseases|September 13, 2023
Sharing Lessons Learned to Build Effective Hepatitis Elimination ProgramsMing-Lung Yu, John W Ward
Alimentary Pharmacology & Therapeutics|May 15, 2026
Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline-A Step Toward Functional Cure or a Marginal Margin?Yao-Chun Hsu, Ming-Lung Yu
Clinical and Molecular Hepatology|February 19, 2024
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answerPin-Nan Cheng, Ming-Lung Yu
Clinical and Molecular Hepatology|March 5, 2024
Correspondence on Letter regarding "Toward hepatitis C virus elimination using artificial intelligence"Ming-Ying Lu, Ming-Lung Yu
The Kaohsiung Journal of Medical Sciences|November 27, 2023
Hepatitis C virus micro-elimination in people who inject drugs: Challenges and chance in Taiwan and worldwideChi-Ming Tai, Ming-Lung Yu
Clinical and Molecular Hepatology|February 12, 2019
Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?Chung-Feng Huang, Ming-Lung Yu
Journal of the Formosan Medical Association = Taiwan Yi Zhi|July 26, 2018
Reply to "Rescue for interferon failures in HCV genotype 1/HBV dually infection"Meng-Hsuan Hsieh, Ming-Lung Yu
Hepatitis Research and Treatment|January 22, 2011
Pegylated interferon and ribavirin treatment for hepatitis C virus infectionTatehiro Kagawa, Emmet B Keeffe, Ming-Lung Yu
Pageof 62